BioVentrix has announced the first clinical use of its closed-chest Revivent TC transcatheter ventricular enhancement system at the Deutsches Herzzentrum Berlin in Berlin, Germany. The less invasive ventricular enhancement (LIVE) procedure was performed by interventional cardiologist Christoph Klein and cardiothoracic surgeon Felix Hennig, with contributions from Sebastian Kelle, chief of cardiovascular imaging at the centre.
The device was successfully implanted with two micro-anchor pairs in a 52-year-old male patient suffering from ischaemic heart failure. The procedure reshaped the left ventricle and decreased the left ventricular end systolic volume index (LVESVI). By remodelling the left ventricle to a more normal shape and size, the implant is designed to improve pumping efficiency, decrease wall stress, and immediately reverse patient symptoms.
“We are impressed by the immediate impact of the less-invasive Revivent TC system,” says Kelle. “The patient achieved a 33% reduction in LVESVI and a 15% increase in the ejection fraction,” continues Kelle.
“The therapy provides a much-needed option for patients suffering from heart failure due to left ventricular anterior scar, particularly when medical therapy is no longer effective. We are impressed by the immediate improvements and are eager to learn about the long term results of this promising method,” says Klein.
“This patient’s quality of life was severely impacted by his heart failure,” says Hennig. “Especially for an older and more fragile population, the risks and recovery of surgery often preclude any meaningful intervention. The LIVE procedure eliminates the invasive elements associated with conventional surgical reconstruction. It expands the patient population that will be able to benefit from this procedure,” continues Hennig.
